This is the author-created version of the following work:


Access to this file is available from:
https://researchonline.jcu.edu.au/65970/

Published Version: (C) 2020 Elsevier Ltd. All rights reserved, Accepted Version: Open Access in an Institutional Repository under a CC BY-NC-ND license after an embargo of 12 months.

Please refer to the original source for the final version of this work:
https://doi.org/10.1016/j.vaccine.2020.11.005
Cooling to reduce pain associated with vaccination: a systematic review

Abstract

Background: Vaccine injections are the most common cause of iatrogenic pain in childhood and a cause of anxiety in adulthood. Skin cooling techniques, including icepacks and vapocoolants, may provide pain relief during intramuscular injections.

Objective: To identify the effects of skin cooling techniques on pain associated with immunisation.

Methods: MEDLINE (Ovid), CINAHL, EMCARE, INFORMIT and Scopus were searched for randomised controlled trials (RCTs) investigating the use of skin cooling techniques on pain associated with vaccination. Study and intervention details, outcomes measures and results were extracted and risk of bias assessed using the Cochrane Risk of Bias tool. Due to heterogeneity of studies, a narrative synthesis was performed.

Results: Thirteen trials were included, involving 689 paediatric and 829 adult participants. All studies used vapocoolant or ice as one of the interventions. Comparator groups included topical EMLA cream, breastfeeding, distraction techniques and tactile stimulation. Vapocoolant reduced vaccination-related pain in all adult studies and six paediatric studies however the use of ice packs in paediatric patients was not effective.

Conclusion: The use of cooling techniques reduces pain associated with vaccinations in adults. Paediatric studies show mixed results for vapocoolants and an inability for ice to decrease vaccine-injection pain. Larger RCTs are required to determine the most effective administration techniques and optimise the analgesic effects of skin cooling.

Keywords: Pain, vaccination, immunisation, vapocoolant, ice, cooling
Introduction

Vaccine injections are the most common cause of iatrogenic pain in childhood (1) and anxiety in up to 90% of adults (2). Injection-associated pain and anxiety is a contributing factor to future non-compliance with scheduled vaccinations throughout the lifespan (3,4). Vaccinations are heralded as saving up to 3 million lives each year (5) and are the cornerstone of herd immunity, therefore interventions to reduce the pain and anxiety of intra-muscular vaccinations, and consequently reduced immunisation rates, warrant further investigation (6). A study of an adult working population found that 97% of participants chose to receive intranasal influenza vaccine over its injectable equivalent, with 14% citing fear of injections as the primary reason for choosing the intranasal route of administration (7). Pain associated with immunisation is now recognised as a significant adverse event, and adequate pain management strategies should therefore be incorporated into every vaccination (8).

Previous systematic and literature reviews in paediatric populations (9,10) and combined paediatric and adult populations (11), have investigated interventions to reduce the pain of immunisation. Topical analgesics were found to be effective in both adult (11) and paediatric populations (9,10), as were sucrose solutions, breastfeeding in the 0-2 year age group (9) and cooling combined with vibration(10) however cooling alone has yielded mixed results.

Cold therapy has been used for centuries to mitigate pain (12). Pain reduction begins at the threshold of 10°C and continues to increase as skin temperature approaches 0°C (13). The analgesic effect of vapocoolant sprays and ice-packs is further enhanced by their ability to suppress the autonomic responses by decreasing skin conduction level and blood flow (14). In addition to these effects, cooling techniques are considered to be cost-effective and have few, if any, side effects when applied correctly (2).

This review aims to identify and synthesise randomised controlled trials (RCTs) investigating the use of ice or vapocoolant spray to reduce the pain of immunisation in paediatric and adult populations.
Materials and methods

This study was prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42020140084) and guided by the ‘Preferred Reporting Items for Systematic Reviews and Meta-Analyses’ (PRISMA) guideline (15).

Literature search

A comprehensive literature search, developed in consultation with the Cochrane Collaboration guidelines (16), of the MEDLINE (Ovid), CINAHL, EMCARE, INFORMIT and Scopus databases was conducted on 24th May 2019. The search strategy included MeSH terms and key words related to the intervention: “immunisation”, “vaccinations”, “injections”, “cold therapy”, “ice packs” and “vapocoolant”. These search terms were adapted for use with each bibliographic database in combination with database-specific filters. The search was restricted to studies published in the English language. A final search of the databases was conducted on 23rd August 2019 prior to final data analysis.

All articles identified by search were independently screened for eligibility by two reviewers (YE and LH). Bibliographies of included studies were hand-searched for additional articles meeting the selection criteria. Discrepancies between reviewers were resolved by an independent third reviewer (CH).

Selection criteria

Randomised controlled trials that investigated the use of cold techniques (e.g. ice-packs, vapocoolants) in people undergoing vaccine injections in any setting (e.g. hospital or community) were included. No restrictions were placed on the age of participants. Studies of needle-related procedures other than vaccine injections (e.g. venepuncture and venous cannulation) were excluded.

Data extraction and quality assessment

Data from included studies were independently extracted into standardised spreadsheets by two reviewers (YE and LH) and compared for accuracy. Discrepancies were resolved by a third reviewer (CH). The following data were tabulated: author name and year, study setting and design, participant characteristics, interventions and outcome measures used, results and key conclusions.
The methodological quality of included studies was independently assessed by two reviewers (YE and AN) using the Cochrane risk-of-bias tool for RCTs (The Cochrane Collaboration) (16). Disagreements were resolved by a third reviewer (CH). Studies were categorised as low risk of bias if all seven domains were rated as low risk; unclear risk of bias if any domains were rated as unclear; and high risk of bias if one or more domains were rated as high risk.

Outcome measures

The primary outcome measure was pain associated with vaccination, measured using self-reported pain scales, parent-reported pain scales, infant crying time or infant behaviour scales. A meta-analysis was not possible due to the small sample size, heterogeneity of data and the lack of equivalent comparator groups across studies. Consequently, a narrative synthesis of the data was conducted.

Results

The search strategy identified 428 studies of potential relevance. After duplicates were removed, 404 studies were screened by title and abstract and 13 full texts assessed for eligibility. Four additional studies were included after manual reference searches (Figure 1). Ten studies involving paediatric participants (n=689) and three involving adult (> 18 years of age) participants (n=829) undergoing vaccination were included in this review. The majority of trials were conducted in the United States of America (n=8) and Canada (n=2) (Table 1).

All studies used ice or vapocoolant as an intervention. The comparator groups were usual care/no intervention (17-23) and/or various physical and pharmacological interventions. These included distraction methods (17,24,25), topical anaesthetic cream (24-26), breastfeeding (21,26), cold saline (2), compressed air (22,27,28), and tactile stimulation (25). The number of vaccinations administered during trials ranged from one to six successive injections. Sample sizes tended to be smaller in the paediatric studies than adult studies, with all except Boroumandfar et al having less than 100 participants.

Studies conducted in paediatric populations

Paediatric studies included infants and children up to 18 years of age, three of which investigated use of cooling techniques with injection of various vaccines, most commonly
diphtheria-tetanus-pertussis vaccine (acellular and whole-cell forms) (19,21-24,26-28) (Table 1). Other vaccinations included measles-mumps-rubella (23), Hepatitis B (21) and tetanus (20). Ice was used as the skin cooling technique in two paediatric studies (19,20), the remaining using vapocoolant either sprayed directly onto the skin (17,21,26-28) or applied via vapocoolant-soaked cotton balls (22-24) in an attempt to control for the potential confounding effect of the spray being perceived as a noxious stimulus.

Ice

Both studies that assessed the efficacy of ice in reducing pain associated with vaccination found it was ineffective. Self-reported pain levels (Faces Pain rating scale) did not differ with the application of ice for 15 minutes prior to injection of the tetanus vaccine in children aged 10 to 18 years in the study by Ebner et al (20). Application of ice for 30 seconds in the study by Gedaly-Duff and Burns (19) made no difference to pain levels as reported by both the children participating (using the Wong-Baker Faces and Oucher scales) or the observer (using the Global Mood Scale and pulse rate).

Vapocoolant

Five trials showed efficacy of vapocoolant sprays in reducing vaccination pain or distress. Vapocoolant spray and compressed air both reduced pain of vaccination in children aged four to 6 years compared to no intervention (22). From this, Abbott and Fowler (22) concluded that cognitive processes altered pain processing and associated responses such that the placebo intervention was equally as effective as the intervention itself.

Boroudmandfar et al (21) concluded from observer assessment using the Neonatal Infant pain scale that both cooling and breastfeeding were superior to usual care in reducing pain but breastfeeding was most effective. In a 2 X 2 factorial design that involved vapocoolant spray or compressed air with or without cognitive information, Eland (28) reported reduced pain levels with vapocoolant regardless of the information provided about the intervention and, in contrast to Abbott and Fowler (22), that vapocoolant was more effective at reducing pain than a placebo air spray.

Cohen Reiss et al demonstrated that vapocoolant spray (combined with distraction) reduced distress, pain VAS and cry time immediately post-vaccination compared with the distraction-control group (24), however differences in distress were not maintained five minutes post-
injection. No difference was found between vapocoolant spray and EMLA cream. Maikler et al reported that vapocoolant spray did not reduce cry duration compared to compressed air but cry latency and distress behaviours at the time of injection were reduced (27).

Three vapocoolant studies found no efficacy for this cooling technique to reduce vaccination pain in the paediatric population. Pain and distress during vaccination, as assessed using self-, carer- and observer-measures, did not differ between vapocoolant and usual care in children aged four to six years in the study by Cohen et al (23). Similarly, Gupta found no evidence of efficacy of vapocoolant sprays post-vaccination (26). These authors concluded that the addition of topical EMLA or vapocoolant spray to breastfeeding does not decrease the duration of cry immediately post-vaccination but both interventions reduced Neonatal Infant Pain Scale scores at one and three minutes after injection (26). The study by Luthy et al relied on parental perceptions of their child’s pain and anxiety post-vaccination (17). In contrast to Cohen Reis et al vapocoolant spray was shown to be no more effective than distraction techniques (watching a DVD) or usual care (17).

Studies conducted in adult populations

Ice

Of the three studies investigating cooling techniques in adults, only one incorporated ice as one of the intervention arms (18). Ice applied to the skin for 30 seconds was shown to reduce pain during needle insertion and administration of the tetanus vaccine compared to usual care (no treatment) in the study by Akcimen et al (18). There was no difference in pain VAS between ice and vapocoolant spray (a second intervention arm of this study) at the time of needle insertion however scores were significantly lower in the ice group when the vaccine was introduced.

Vapocoolant

All three adult studies used vapocoolant as an intervention. Akcimen et al (18) reported effectiveness of vapocoolant sprayed directly onto the skin in reducing pain compared to usual care at the time of needle insertion, however pain levels were significantly higher with introduction of tetanus vaccine.
Mawhorter et al demonstrated a decrease in pain immediately post-vaccination with the application of vapocoolant to the skin via a cotton ball compared to cold saline (4°C) (2). The difference in pain between the two groups was not evident five minutes post-injection. Taddio et al provided a comparison of vapocoolant spray (applied directly to the skin) to topical anaesthetic (liposomal lidocaine), tactile stimulation and distraction (reading a magazine) (25) that revealed no efficacy for the cooling technique however topical anaesthetic reduced self-perceived pain compared to distraction. Whilst using vapocoolant spray as one of the group allocations, the primary aim of the study by Taddio et al was to determine the effectiveness of topical anaesthesia compared to vapocoolant spray, tactile stimulation and distraction. The effectiveness of vapocoolant and topical anaesthesia did not differ but no summary statistics were provided to allow comparison of vapocoolant to tactile stimulation and distraction.

Risk of bias

Three studies were considered at high risk of bias, two due to lack of or inadequate blinding of participants (17,18) and one due to potential selection bias (20). All other included studies were considered to be at unclear risk of bias (Figure 2).

Discussion

Thirteen studies that investigated the efficacy of skin cooling techniques in reducing pain associated with vaccinations in adults and children were reviewed. Adult studies more consistently demonstrated a reduction in pain with skin cooling interventions compared to those in the paediatric population. Potential reasons for this include differences in: outcome measures and participant age, comparator groups, vaccine/s administered and application of the cooling technique. Each of these are discussed below.

Outcome measures and participant age

The subjective nature of pain makes is difficult to measure and often relies on gold standard self-reporting of pain levels using validated instruments e.g. visual analogue scale (VAS). Self-reported scales are not considered applicable to children less than three years of age(29) therefore this difficulty is compounded in infants and young children. As such surrogate measures are used based commonly on behavioural and physiological changes.
Adult studies in this review relied on self-reported pain using Pain VAS and McGill Present Pain Intensity, both of which have been validated (30,31). Paediatric studies relied on several different outcome measures which varied depending on participant age. Luthy et al used parental perception of their child’s pain, despite including participants from two to 12 years of age (17). Potential differences in surrogate reports of pain by parents and those the children, as demonstrated by Abbott and Fowler (22), may have self-reported could have contributed to the lack of efficacy of vapocoolant in this study.

**Comparator groups**

Not all studies utilised a usual care or no-intervention control group, instead opting to either use a combined intervention in which one component was carried through all comparator groups (e.g. vapocoolant+distraction, EMLA cream+distraction and distraction alone (24)), or a control group that closely resembles the intervention (e.g. vapocoolant spray and compressed air (27)). In each of these cases, the effect of cooling may be mitigated by the effect of the common or comparator intervention. Gupta et al used breastfeeding as an intervention common to each randomised group, however breastfeeding alone has been shown to be effective in reducing pain associated with vaccination (11). It is possible that non-pharmacological interventions act like a filter (e.g. breastfeeding) in which a certain level of pain passes through but higher pain is attenuated. Although additional filters may be added (for example breastfeeding+vapocoolant) the effect of combined filters may be synergistic and therefore the reduction in pain may not be proportional to the effect of each individual intervention filters.

In a similar manner, Ebner conducted her study in a cohort of children receiving tetanus vaccinations in an emergency department after presentation with wounds that potentially required suturing (20). Attention influences the spinal gating mechanism that modulates pain (32). Depending on the severity of the wound, it could garner more attention than the vaccination, in which case the potential analgesic effect of ice may have been diminished by the distraction of the wound itself.

**Vaccine/s administered**

The pain or discomfort from the injections is the combined result of local tissue injury from the needle insertion and the introduction of the vaccine, which increases intra-tissue
pressure as the volume increases. Thus, higher volumes of vaccines may cause more pain at
the injection site than lower volumes. Different vaccinations may also be perceived as more
painful than others. For example, Burns et al showed that pain scores for Human Papilloma
Virus vaccination were higher than Hepatitis A and meningococcal vaccinations (33). Studies
in children receiving the DPT vaccine showed vapocoolant was effective (either immediately
or within 3 minutes of injection) in reducing pain levels.

The number of vaccinations administered differed between trials. All studies that used
vapocoolant in infants and children who received two or less vaccines in the one
consultation reported positive effects of cooling either immediately (21, 22, 24, 26, 27, 28) or
post-vaccination (26). Those that allowed for multiple injections (17, 23) had less favourable
outcomes. This did not hold true in single-injection paediatric studies that used an ice
intervention. The order of injection of multiple vaccinations can affect the pain response in
infants given the first injection may focus attention and stimulate pain-processing
mechanisms that intensify subsequent signals (34). Neither study that allowed for multiple
vaccinations stated if the order of vaccine administration was randomised.

Application of cooling techniques

Any intervention applied prior to injection could focus participant’s attention on the site to
which it is applied and heighten the pain response. Vapocoolants cause cold and often
burning sensations of the skin that can be perceived as noxious stimuli, increasing distress
and anxiety (23) and potentially mitigating any benefit from their application. Eight studies
across the lifespan demonstrated a benefit of vapocoolants in reducing vaccination pain,
therefore this is unlikely to explain the inconsistent results.

There appears to be little consensus on the most effective technique to apply cooling
interventions. This review identified studies that applied ice for as little as 30 s (18, 19) or up
to 15 minutes (20). The time for which vapocoolants were applied was less variable (2-10 s
when sprayed directly onto the skin and 10-20 s when applied via soaked cotton balls) and
reflects the potential for these volatile liquids to cause skin freezing. These differences in
the technique used in applying the intervention do not account for the variable results. Both
paediatric studies that used ice as an intervention showed no difference in pain levels
compared to usual care despite the short and long durations of application. Similarly,
studies in similar aged participants that used soaked cotton balls as a vehicle for vapocoolants had contradicting results (22,23).

**Limitations**

The methodological heterogeneity of the included trials in terms of sample size, intervention, comparator groups and measured outcomes meant a meaningful meta-analysis could not be performed. Additionally, although there were 10 paediatric studies, compared to three in the adult population, their numbers contributed to only 45% of total participants studied, indicating a need for larger scale RCTs in this group.

Another limitation of this review is that all studies were considered to be either at unclear (n=10) or high risk of bias (Figure 2), commonly due to performance and reporting biases. The results of this review should therefore be interpreted with caution.

The effectiveness of vapocoolant in the study by Taddio et al (25) was difficult to determine as it was compared to other interventions without a usual care or no-intervention control. The remaining two studies (2,18) suggest that skin cooling using vapocoolant sprays can be recommended as a form of analgesia to reduce pain associated with vaccine injections in adults. Ice shows promise in mitigating immediate vaccination-related pain (18) but further research is required to replicate these findings.

**Clinical implications**

Further research is needed to assess the effectiveness of skin cooling techniques, particularly in infants and children, as a viable method of reducing immunisation pain. However, based on current evidence, the use of vapocoolant sprays in adults can successfully be implemented in primary healthcare settings. Both ice and vapocoolant have few adverse effects, are cost effective and can be easily applied to injection sites. Vapocoolants have the advantage of providing instantaneous cooling effects to the skin, increasing efficiency while ice has widespread availability with minimal cost.

**Conclusions**

The use of skin cooling techniques may effectively reduce the pain associated with vaccine-injections. Whilst paediatric study findings are inconclusive, this review concludes that the use of vapocoolant spray and ice in adults can successfully decrease pain associated with vaccination. More rigorous and larger-scale RCT study designs are needed to determine the
effectiveness and applicability of skin cooling techniques for reducing immunisation pain in primary healthcare settings. These should aim to determine to what extent pain mitigation is dependent on the nature of the intervention, the specific vaccine, and age group of participants.

Acknowledgements

The authors would like to thank Mr Stephen Anderson, medical librarian, James Cook University, for his assistance with this systematic review.

Funding

Nil

Conflict of interest statements

None of the authors have any conflict of interests to declare.
References


Figure 1: PRISMA flow diagram

Figure 2: Summary of risk of bias - Author's assessment of methodological quality of individual studies. Low risk in green (+), unclear risk in yellow (?), high risk in red (−).
Table 1: Details of studies included in narrative review

<table>
<thead>
<tr>
<th>First author, year, country</th>
<th>Participant age</th>
<th>Vaccine and injection details [number of vaccinations received]</th>
<th>Cooling Intervention</th>
<th>Comparator group</th>
<th>Outcome measures (reported by)</th>
<th>Results (cooling intervention compared to comparator group/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PEDIATRIC STUDIES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Abbott 1995 Canada (22)     | 4-5.5 y (n=90)  | DPT; IM; deltoid muscle - needle gauge and volume of injectable solution constant but length of needle and injection technique varied [1] | Refrigerant topical anesthetic spray (Fluroethyl) (n=30) | 1) Placebo topical spray (compressed air + Freon) via sterile cotton ball for 10 s (n=30); 2) No-treatment control (n=30) | Pain VAS (child); Anxiety and expected pain VAS (parent) | 1) No difference  
2) Anesthetic spray reduced pain compared to no-treatment control |
| Boroumandfar 2013 Iran (21) | <6mo (n=144)    | Hepatitis B (35%) and DTP (65%); injection details NR [2] | Vapocoolant spray (n=48) | Directly to injection site (1-3 s from 15 cm away) | Neonatal infant pain scale (NIPS) 2 pain assessment checklist (researcher) | 1) Frequency of painless injection higher in breastfeeding group than vapocoolant group  
2) Vapocoolant spray reduced pain severity compared to no-treatment control group |
<p>| Cohen 2009 USA (23)         | 4-6 y (n=57)    | DPTaP, measles-mumps-rubella and inactive polio vaccine; 25-G 1 inch needle in thigh [3] | Vapocoolant (Ethyl Chloride) (n=31) | Soaked cotton ball (20 s) | Faces pain scale revised (child); Baseline distress VAS (parent and nurse); Immunisation distress VAS (parent and nurse); | No difference |</p>
<table>
<thead>
<tr>
<th>Study</th>
<th>Age Range</th>
<th>Vaccine Details</th>
<th>Pain Management</th>
<th>Measures Assessed</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohen Reis 1997 USA (24)</td>
<td>4-6 y (n=62)</td>
<td>DTaP; IM; 26-G 1/2 inch needle in deltoid [1]</td>
<td>Vapocoolant (Fluoromethane) spray + distraction (n=20)</td>
<td>1) EMLA cream for 60 min + distraction (blow on pinwheel) (n=21) 2) Distraction alone (control) (n=21)</td>
<td>Prior experience VAS (parent); Global mood scale (researcher); Observation scale of behaviour distress (researcher); Linear pain VAS (parent, nurse, researcher); Cry duration (researcher); Parental distress VAS (parents own level of distress), Parental preference VAS (parents) 1) No difference 2) Vapocoolant reduced injection pain compared to control group for all measures except Global mood scale (researcher)</td>
</tr>
<tr>
<td>Ebner 1996 USA (20)</td>
<td>10-18 y (n=40)</td>
<td>Tetanus; Injection details NR [1]</td>
<td>Ice (n=NR)</td>
<td>No-treatment control (n=NR)</td>
<td>Faces Pain rating scale (child) No difference</td>
</tr>
<tr>
<td>Eland 1981 USA (28)</td>
<td>4y9mo to 5y9mo (n=40)</td>
<td>DPT 0.5 ml; IM; 25-G 5/8 inch needle in vastus lateralis [1]</td>
<td>Frigiderm spray + cognitive information (n=10) OR Frigiderm + no cognitive information (n=10)</td>
<td>1) Aerosol air spray + cognitive information (n=10) 2) Aerosol air spray (n=10). Spray applied 3-5 s on the leg before vaccination</td>
<td>Colour assessment tool (child); Anxiety (parent and nurse) 1) Frigiderm spray reduced pain compared to air spray + cognitive information; 2) Frigiderm spray reduced pain compared to air spray</td>
</tr>
<tr>
<td>Gedaly-Duff 1992 USA (19)</td>
<td>4-6 y (n=38)</td>
<td>DPT (78%) or DT (22%); 25-G 5/8 inch needle (84%); deltoid (76%) [1]</td>
<td>Ice (n=19)</td>
<td>No-treatment control (n=19)</td>
<td>Global mood scale (GMS) (observer); Radial pulse rate (observer); Oucher scale and Wong-Baker Faces scale (child) No difference</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Age Range</td>
<td>Vaccine</td>
<td>Needle Type</td>
<td>Vapocoolant</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>-----------</td>
<td>---------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Gupta 2017 India (26)</td>
<td>&lt;3 mo (n=90)</td>
<td>wDPT; IM; 23-G 1 inch needle in anterolateral thigh [1]</td>
<td>Vapocoolant spray + breastfeeding (n=30)</td>
<td>Directly to injection site (2 s from 12 cm away)</td>
<td>1) EMLA cream 1g for 60 mins + breastfeeding (n=30)</td>
</tr>
<tr>
<td>Luthy 2013 USA (17)</td>
<td>2-12 y (n=68)</td>
<td>Vaccine NR; injection details NR [1-&gt;4]</td>
<td>Vapocoolant spray (n=18)</td>
<td>Directly to injection site (3-7 s)</td>
<td>1) Distraction (DVD before, during, and after injection (n=27) 2) No-treatment control (n=22)</td>
</tr>
<tr>
<td>Maikler 1991 USA (27)</td>
<td>6-30 weeks (n=60)</td>
<td>DPT; IM; 25-G 5/8-inch needle in anterior thigh [1]</td>
<td>Frigiderm spray (dichloretetrafluorethane) (n=30)</td>
<td>Directly to injection site (2-3 s)</td>
<td>Compressed air spray (2-3 s directly to skin) (n=30)</td>
</tr>
</tbody>
</table>

ADULT STUDIES
<table>
<thead>
<tr>
<th>Study/Location</th>
<th>Age</th>
<th>Intervention Details</th>
<th>Pain Assessment/Outcome</th>
<th>Further Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akcimen 2019, Turkey (18)</td>
<td>&gt;18 y (n=292)</td>
<td>Tetanus 1 ml; IM; 25-G needle in deltoid [1] 1) Ice (n=107) Ice: cube in latex glove (30 s); 2) Vapocoolant spray (Nexcare® Coldhot) (n=90)</td>
<td>Pain VAS (patient)</td>
<td>1) Ice reduced pain compared to control group 2) Vapocoolant reduced pain compared to control group</td>
</tr>
<tr>
<td>Mawhorter 2004 USA (2)</td>
<td>&gt;18 y (n=185)</td>
<td>Varied travel vaccines; IM and SC; injection details NR [2-6] 1) Vapocoolant (Fluoromethane) (n=93) 2) Vapocoolant (4°C saline via cotton ball (n=92))</td>
<td>McGill present pain intensity (PPI) (patient)</td>
<td>Vapocoolant reduced immediate injection pain compared to untreated arm; effect not maintained at 5 minutes post injection</td>
</tr>
<tr>
<td>Taddio 2010, Canada (25)</td>
<td>Adults (n=352)</td>
<td>H1N1 virus vaccine 0.5mL, 22-G 1 inch needle in middle deltoid [1] 1) Vapocoolant spray (PainEase Medium spray) (n=88) 2) Directly to injection site within 60 s of injection (4-10 s) 3) 1–2 g of liposomal lidocaine 4% cream on injection site for 20–30 mins (n=88) 2) Nurse-directed tactile stimulation for 10 s before and during injection (n=88) 3) Self-directed distraction before and during injection (n=88)</td>
<td>Pain VAS (patient); Anxiety VAS (patient); Predicted pain VAS (patient); Global assessment of intervention (patient)</td>
<td>1) No difference 2) Comparison not provided 3) Comparison not provided</td>
</tr>
</tbody>
</table>

DPT = diphtheria, pertussis, tetanus; DTaP = diphtheria, tetanus, acellular pertussis; IM = intramuscular; NR = not reported; VAS = visual analogue scale; wDPT = whole cell diphtheria, pertussis, tetanus.